Skip to main content

Financial Toxicity and Equitable Access to Clinical Trials.

Publication ,  Journal Article
Chino, F; Zafar, SY
Published in: Am Soc Clin Oncol Educ Book
January 2019

Financial barriers to clinical trial enrollment are an area of active investigation. Financial toxicity as a concept describes how high costs and financial burden can lead to compromised care and outcomes. Despite the potential to yield large survival benefits and improved access to cutting-edge therapies, less than 5% of adult patients with cancer are enrolled in a clinical trial. Disparities in trial enrollment exist along age, ethnic, and sociodemographic lines, with younger, poorer, nonwhite patients with private insurance-the exact population who may be at highest risk for financial toxicity-less likely to participate. Cost and insurance concerns remain an obstacle for clinical trial enrollment for certain patient populations. Changing the clinical trial paradigm with a focus on addressing structural and clinical barriers to clinical trial enrollment is paramount. This includes expanding access to clinical trials within community populations, advocating for health policy changes to guarantee insurance coverage of clinical trial standard-of-care health care, and considering noncoercive financial assistance (particularly for indirect costs like travel and lodging) for participants to defray their additional costs of participation. Additional steps toward education, cost transparency, and expansion of foundation assistance may also improve equitable access to clinical trials for all.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Soc Clin Oncol Educ Book

DOI

EISSN

1548-8756

Publication Date

January 2019

Volume

39

Start / End Page

11 / 18

Location

United States

Related Subject Headings

  • United States
  • Patient Participation
  • Neoplasms
  • Humans
  • Healthcare Disparities
  • Health Services Accessibility
  • Health Care Costs
  • Cost of Illness
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chino, F., & Zafar, S. Y. (2019). Financial Toxicity and Equitable Access to Clinical Trials. Am Soc Clin Oncol Educ Book, 39, 11–18. https://doi.org/10.1200/EDBK_100019
Chino, Fumiko, and S Yousuf Zafar. “Financial Toxicity and Equitable Access to Clinical Trials.Am Soc Clin Oncol Educ Book 39 (January 2019): 11–18. https://doi.org/10.1200/EDBK_100019.
Chino F, Zafar SY. Financial Toxicity and Equitable Access to Clinical Trials. Am Soc Clin Oncol Educ Book. 2019 Jan;39:11–8.
Chino, Fumiko, and S. Yousuf Zafar. “Financial Toxicity and Equitable Access to Clinical Trials.Am Soc Clin Oncol Educ Book, vol. 39, Jan. 2019, pp. 11–18. Pubmed, doi:10.1200/EDBK_100019.
Chino F, Zafar SY. Financial Toxicity and Equitable Access to Clinical Trials. Am Soc Clin Oncol Educ Book. 2019 Jan;39:11–18.

Published In

Am Soc Clin Oncol Educ Book

DOI

EISSN

1548-8756

Publication Date

January 2019

Volume

39

Start / End Page

11 / 18

Location

United States

Related Subject Headings

  • United States
  • Patient Participation
  • Neoplasms
  • Humans
  • Healthcare Disparities
  • Health Services Accessibility
  • Health Care Costs
  • Cost of Illness
  • Clinical Trials as Topic
  • 3211 Oncology and carcinogenesis